OncoMatch/Clinical Trials/NCT04210492
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Is NCT04210492 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for non-small cell lung cancer.
The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Smilow Cancer Hospital Care Center at Greenwich · Greenwich, Connecticut
- Smilow Cancer Hospital Care Center - Guilford · Guilford, Connecticut
- Smilow Cancer Hospital - Hamden Care Center · Hamden, Connecticut
- Smilow Cancer Hospital · New Haven, Connecticut
- Smilow Cancer Hospital Care Center - Trumbull · Trumbull, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify